Guessing it was this e-mail sent out today that got things moving a bit - lets hope it continues.
ABC 7.30 coverage on Linear vaccine study using Emerald’s Sentinel Plus
Emerald Clinics Limited (ASX:EMD) is pleased to inform investors and interested parties that the COVID-19 vaccine study being conducted by Linear Clinical Research, for which Emerald’s Sentinel Plus service will provide remote monitoring and clinical evaluation, was featured on ABC’s 7.30 program on Monday 6 July.
The Sentinel Plus service was chosen by Linear to provide clinical evaluation support for 150 participants involved in the two-year vaccine trial. Sentinel Plus is backed by Emerald’s clinical team and incorporates Emerald’s Real-World Evidence engine, as well as smartphone and artificial intelligence technology, to help monitor and evaluate vital signs and other clinical and symptom data from trial participants who develop symptoms during the course of the trial.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)